Chemotherapy in Treating Women With Metastatic Breast Cancer
NCT00004046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2012-05-16
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating women who have metastatic breast cancer that has not responded to previous therapy.
Conditions
Interventions
- DRUG
-
exatecan mesylate
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Robert L. DeJager, MD, FACP · Daiichi Sankyo
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-06-30
- Primary Completion
- 2002-04-30
- Completion
- 2002-04-30
Countries
- United States
Study Locations
More Related Trials
-
Chemotherapy Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer
NCT00003953 ·Status: COMPLETED ·Phase: PHASE2
-
Doxorubicin in Treating Women With Advanced Breast Cancer
NCT00003165 ·Status: UNKNOWN ·Phase: PHASE2
-
Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy
NCT00070031 ·Status: COMPLETED ·Phase: PHASE2
-
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00028639 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
NCT00004906 ·Status: COMPLETED ·Phase: PHASE2
-
Study of MDX-010 in Stage IV Breast Cancer
NCT00083278 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
NCT00079118 ·Status: COMPLETED ·Phase: PHASE2
-
S0029 Docetaxel in Treating Older Women With Metastatic Breast Cancer
NCT00025493 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Weekly Taxotere and Xeloda in Metastatic Breast Cancer
NCT00214864 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT00461344 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
NCT00080626 ·Status: TERMINATED ·Phase: PHASE2
-
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer
NCT00206453 ·Status: TERMINATED ·Phase: PHASE2
-
Docetaxel Combined With Ketoconazole in Treatment of Breast Cancer
NCT00212095 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer
NCT00574236 ·Status: TERMINATED ·Phase: PHASE2
-
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
NCT00496808 ·Status: COMPLETED ·Phase: NA
-
Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
NCT00001493 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927 ·Status: COMPLETED ·Phase: PHASE1
-
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
NCT00423917 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy in Treating Women With Previously Treated Metastatic Breast Cancer
NCT00003236 ·Status: COMPLETED ·Phase: PHASE2
-
PS-341 in Treating Women With Metastatic Breast Cancer
NCT00025584 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer
NCT00003972 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer
NCT00079170 ·Status: COMPLETED ·Phase: NA
-
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
NCT01277757 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
NCT04095689 ·Status: TERMINATED ·Phase: PHASE2